Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud’s Phenomenon Secondary to Systemic Sclerosis
Condition(s):Systemic Sclerosis; Raynaud DiseaseLast Updated:June 24, 2005Completed
Hide Studies Not Open or Pending
Condition(s):Systemic Sclerosis; Raynaud DiseaseLast Updated:June 24, 2005Completed
Condition(s):Raynaud’s Disease; Peripheral Vascular DiseaseLast Updated:May 16, 2018Completed
Condition(s):Raynaud Disease; Raynaud Disease Secondary to Scleroderma; Raynaud Secondary to Other Autoimmune DiseaseLast Updated:May 30, 2007Completed
Condition(s):Primary Raynaud Disease; Systemic SclerosisLast Updated:March 24, 2016Completed
Condition(s):Raynaud Phenomenon; Primary Raynaud Phenomenon; Raynaud Disease; Raynaud SyndromeLast Updated:November 5, 2020Terminated
Condition(s):Raynaud’s Phenomenon; Skin NecrosisLast Updated:December 15, 2014Unknown status
Condition(s):Buerger Disease; Raynaud SyndromeLast Updated:July 12, 2023Not yet recruiting
Condition(s):Raynaud Disease; Hyperemia; ColdLast Updated:December 9, 2015Unknown status
Condition(s):Raynaud’s Disease; Scleroderma; Autoimmune DiseasesLast Updated:May 30, 2007Completed
Condition(s):Raynaud’s Disease; Raynaud’s Disease Secondary to Scleroderma; Raynaud’s Disease Secondary to Other Autoimmune DiseaseLast Updated:February 5, 2010Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.